Drug Profile

QRA 101

Alternative Names: QRA-244; QRL-101

Latest Information Update: 28 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Eli Lilly and Company
Developer QurAlis Corporation
Class Antiepileptic drugs; Neuroprotectants; Small molecules
Mechanism of Action KCNQ2 potassium channel stimulants; KCNQ3 potassium channel stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Amyotrophic lateral sclerosis; Epilepsy

Most Recent Events

12 Mar 2025 Efficacy and adverse events data from a phase I trial (In volunteers) released by QurAlis Corporation
12 Mar 2025 QurAlis Corporation plans a proof-of-concept trials for Amyotrophic lateral sclerosis and Epilepsy (PO)
10 Jan 2025 QurAlis Corporation initiates a phase I trial (In Volunteers) in Netherlands (NCT06877624)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com